The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC).
Guru Sonpavde
No relevant relationships to disclose
Joaquim Bellmunt
Research Funding - Pierre Fabre Medicament
Ronan Fougeray
Employment or Leadership Position - Pierre Fabre Medicament
Yacine Salhi
Employment or Leadership Position - Pierre Fabre Medicament
Gregory Russell Pond
No relevant relationships to disclose